Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.56 |
| ▸ | MMP2 | P08253 | 13/20 | 0.56 |
| ▸ | MMP1 | P03956 | 9/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195902 | 0.90 | MMP13 (0.45) | MMP13MMP2MMP1MMP14MMP9 | |
| SCHEMBL1133818 | 0.90 | MMP13 (0.44) | MMP13MMP2MMP1MMP14MMP9 | |
| SCHEMBL2194245 | 0.90 | MMP13 (0.46) | MMP13MMP2MMP1 | |
| SCHEMBL2197069 | 0.82 | MMP13 (0.39) | MMP13MMP2MMP1 | |
| SCHEMBL6769491 | 0.74 | MMP13 (0.77) | MMP13MMP2MMP1 | |
| SCHEMBL6767563 | 0.74 | MMP13 (0.77) | MMP13MMP2MMP1 | |
| SCHEMBL6767568 | 0.74 | MMP13 (0.77) | MMP13MMP2MMP1 | |
| SCHEMBL17923859 | 0.73 | ACACB (0.45) | — | |
| SCHEMBL1133773 | 0.72 | LMNA (0.59) | MMP13MMP2MMP1MMP14MMP9 | |
| SCHEMBL7358588 | 0.72 | MMP13 (0.62) | MMP13MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524194-B2 | Radiolabelled MMP selective compounds | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2013-09-03 | — | — | US | disclosed |
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2011-07-14 | — | — | US | disclosed |
| EP-2285759-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009139634-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139633-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | MMP1, MMP3, MMP9 | MMP13 11/4885MMP2 4/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.